The product is codenamed VR730, and Hikma will be responsible for the clinical development, manufacture and commercialisation of the salmeterol generic, delivered via Vectura's dry powder inhaler.
Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback